Clinica's New Stock Tracker - featured stock: Genoptix
This article was originally published in Clinica
Executive Summary
Stock Highlight: Genoptix (GXDX) +105% The current turbulent global financial markets have sent medtech shares yo-yoing during the first few months of 2008. Financial uncertainty has resulted in the postponement of many IPOs, including that of French ophthalmic equipment specialist Luneau Technology, which cancelled its IPO on the Euronext's Alternext market on January 29.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.